Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02776098 · ClinicalTrials.gov registry record

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

A clinical trial of Cystic Fibrosis, sponsored by Children's Hospital of Philadelphia.

Completed
Registry status
54
Enrollment target
2
Study locations

NCT02776098: Completed study of Cystic Fibrosis, sponsored by Children's Hospital of Philadelphia.

NCT02776098 is a study of Cystic Fibrosis that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 54 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02776098, a study of Cystic Fibrosis, has completed, sponsored by Children's Hospital of Philadelphia.

COMPLETED
Registry status
54 participants
Enrollment target
2
Study locations

Study Summary

This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the presence of glucose intolerance. This is a longitudinal cohort study of 3 main groups: CF subjects without Cystic Fibrosis-related diabetes (CFRD), healthy matched controls and CF subjects with newly diagnosed CFRD started on insulin therapy.

Conditions Studied

Study Locations (2)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2016-05
Est. Completion 2024-03-04
Children's Hospital of Philadelphia

431 total trials

What the finished NCT02776098 record still lists

NCT02776098 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.

NCT02776098 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02776098 about?

NCT02776098 is a clinical study titled "Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance". This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the p...

What is the current status of trial NCT02776098?

This trial is currently completed. The enrollment target is 54 participants. The study started on 2016-05. Estimated completion is 2024-03-04.

What conditions does trial NCT02776098 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

Who is sponsoring clinical trial NCT02776098?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02776098 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02776098's enrollment target sits among peer trials

54 87th of 169 higher than 83 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02776098, the US trial registry maintained by the National Library of Medicine. NCT02776098 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.